Bardy Diagnostics is a well-known player in the AI Biotech/Diagnostic sector. The Seattle-based company focuses on ECG equipment, and is competitive with the other top assignees in the sector including Boston Scientific, Zoll Medical Corporation, and AliveCor. Last week, Bardy Diagnostics received a fresh patent titled "Subcutaneous insertable cardiac monitor optimized for long term, low amplitude electrocardiographic data collection" (U.S. Pub. No. 10736531). This patent teaches a method of inserting a small ECG device directly under the skin for long term heart health monitoring. The system is designed to be under the skin for years at a time without being replaced. 

The system is designed for someone who has previously suffered heart health issues and is required to continuously monitor their heart activity. Once implanted, the device can monitor heart health for years without the wearer having to worry about issues that plague a normal wearable ECG such as it getting wet, falling off, or poor placement. '6531 is Bardy Diagnostic's 5th patent so far in 2020, and the company has been very busy the past 3 years with a total of 7 granted patents and 8 pending applications. To see the full progression of Bardy Diagnostic's patent activity and compare it to their competition, make sure to check out the Magic Number® AI Biotech/Diagnostic Patent Forecast®.